# OnCo record hodgkin-lymphoma (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/hodgkin-lymphoma/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "hodgkin-lymphoma" ;
  schema:name "Hodgkin lymphoma"@en ;
  schema:description "Hodgkin lymphoma is one of the most curable cancers, where the goal is now to cure with less toxicity, using brentuximab and, from 2026, first-line nivolumab."@en ;
  schema:url <https://onco.cc/cancers/hodgkin-lymphoma/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  owl:sameAs <http://www.wikidata.org/entity/Q209369> ;
  schema:citation <https://en.wikipedia.org/wiki/Hodgkin_lymphoma> ;
  onco:tag "heme", "spike" ;
  onco:related <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/pairings/bleomycin-omission-caution/> ;
  onco:technologies <https://onco.cc/technologies/adc/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/imrt-igrt/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/carmustine/>, <https://onco.cc/drugs/chlorambucil/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/mechlorethamine/>, <https://onco.cc/drugs/procarbazine/>, <https://onco.cc/drugs/prednisone/>, <https://onco.cc/drugs/palifermin/> ;
  onco:companies <https://onco.cc/companies/haihe-biopharma/>, <https://onco.cc/companies/bms/>, <https://onco.cc/companies/merck/>, <https://onco.cc/companies/pfizer/>, <https://onco.cc/companies/takeda/>, <https://onco.cc/companies/swog/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/companies/gbg/> ;
  onco:institutions <https://onco.cc/institutions/cruk/>, <https://onco.cc/institutions/mskcc/>, <https://onco.cc/institutions/dana-farber/> ;
  onco:terms <https://onco.cc/terms/deauville-score/>, <https://onco.cc/terms/reed-sternberg-cell/>, <https://onco.cc/terms/lugano-classification/>, <https://onco.cc/terms/pfs/>, <https://onco.cc/terms/os/> ;
  onco:trials <https://onco.cc/trials/ccss/>, <https://onco.cc/trials/nct07188558/>, <https://onco.cc/trials/nct04002297/>, <https://onco.cc/trials/nct06230224/> ;
  onco:journals <https://onco.cc/journals/hematological-oncology/>, <https://onco.cc/journals/journal-of-adolescent-and-young-adult-oncology/> ;
  onco:pipeline <https://onco.cc/drugs/abexinostat/>, <https://onco.cc/drugs/mk-1045/>, <https://onco.cc/drugs/cobolimab/>, <https://onco.cc/drugs/rondecabtagene-autoleucel/>, <https://onco.cc/drugs/krt-232/>, <https://onco.cc/drugs/azd3470/>, <https://onco.cc/drugs/englumafusp-alfa/>, <https://onco.cc/drugs/azd4512/>, <https://onco.cc/drugs/jnj-90014496/>, <https://onco.cc/drugs/ctx112/>, <https://onco.cc/drugs/at101/>, <https://onco.cc/drugs/men1703/>, <https://onco.cc/drugs/cd19-t-hank/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/ideas/idea-chemo-free-hodgkin/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/technologies/ctdna-lymphoma-monitoring/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/targets/cd30/>, <https://onco.cc/trials/hd21/> ;
  onco:standardOfCare <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/fdg-pet/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/terms/deauville-score/>, <https://onco.cc/trials/ahod2131/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/technologies/imrt-igrt/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/echelon-1/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/trials/hd21/>, <https://onco.cc/trials/rathl/>, <https://onco.cc/pairings/pd1-plus-avd-hodgkin/>, <https://onco.cc/trials/swog-s1826/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/pairings/bleomycin-omission-caution/>, <https://onco.cc/technologies/autologous-stem-cell-transplant/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/aethera/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-204/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/trials/checkmate-205/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/ideas/idea-cd30-car-t-hodgkin/>, <https://onco.cc/drugs/brentuximab-vedotin/>, <https://onco.cc/technologies/pet-adapted-therapy/>, <https://onco.cc/companies/childrens-oncology-group/>, <https://onco.cc/trials/ahod1331/>, <https://onco.cc/trials/euronet-phl-c2/>, <https://onco.cc/technologies/cardio-oncology/>, <https://onco.cc/technologies/mammography/> .